跳至主要内容
临床试验/NCT04704791
NCT04704791撤回不适用

Surgical PA-LAA Shunting for Management of Systemic Embolization in Patients With Atrial Fibrillation: a Feasibility Study

Ottawa Heart Institute Research Corporation2 个研究点 分布在 1 个国家开始时间: 2021年3月19日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Composite of device safety and performance

研究概览

简要总结

Atrial fibrillation is common and increases the risk of stroke. Traditionally patients are treated with blood thinning medications or at the time of surgery the part of the heart where blood clots form is cut out. Surgically cutting out the left atrial appendage can be difficult and complications can occur. An alternative strategy is to create a tunnel to increase blood flow and wash out the part of the heart where clots form.

This strategy has not been previously studied. The purpose of this study is to determine if creating a tunnel to increase blood flow is feasible and safe.

详细描述

The goal is to understand the potential avenues to increase Left Atrial Appendage (LAA) flow in patients with Atrial Fibrillation (AF) to minimize systemic embolization risk. Flow modeling demonstrates that the anatomy of the LAA results in decreased velocities in the LAA apex. Introduction of a 3-4mm shunt in the apex can result in increased velocity, less stasis and a lower propensity for thrombus formation. Small (<8mm) inter-chamber shunts can exist in humans with no long term hemodynamic consequences in otherwise structurally normal hearts - making a strategy of pulmonary artery (PA) to LAA shunt an attractive potential therapy given anatomic proximity and gradient differential between the cardiac chambers.

This will be a 5 patient first-in-human feasibility study. The population will include patients undergoing CABG or other cardiovascular surgery with AF and a CHADS2 score >1 in whom the treating team deems traditional therapy with anticoagulants is prohibitive or ineffective (dialysis or EGFR preoperatively <15, previous bleeding with non-reversible pathology, clinically deemed contraindicated to oral anticoagulant). The intervention will be PA-LAA shunt creation at the time of surgery. As this is a single arm study there will be no comparison group.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years undergoing CV surgery
  • History of AF with a CHADS2 score >1
  • Relative contraindication to OAC as determined by the heart team
  • Dialysis or preoperative eGFR of <15
  • Bleeding on DOAC/Coumadin with non-reversible pathology
  • Other medical condition that makes the patient ineligible for OAC
  • Anatomic proximity of LAA and PA on preoperative CT scan suitable for shunt creation

排除标准

  • LVEF <40%
  • History of VTE - either DVT or PE
  • Resting baseline preoperative O2 sats <98%
  • Inability of the patient to provide written informed consent
  • Greater than moderate valvular heart disease which is not to be addressed during surgical intervention
  • Documented mPA to PCWP <5mmHg

结局指标

主要结局

Composite of device safety and performance

时间窗: 3 months

At three months feasibility will be met if there is no: 1. Device related complications 1. Bleeding attributable to device implantation 2. Reintervention (surgical or percutaneous) on the shunt 3. Resting systemic saturations \<92% 4. Documented Qp:Qs \<0.8 2. Device related performance a. Shunt patency at 3 months as assessed by TEE

次要结局

  • Device related performance - maintaining patency(1 year)
  • Systemic saturations(1 year)
  • Systemic embolization(1 year)
  • Need for intervention to close the shunt(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Benjamin Hibbert, MD

MD PhD FRCPC Interventional Cardiologist

Ottawa Heart Institute Research Corporation

研究点 (2)

Loading locations...

相似试验